The aim of this study was to compare the usefulness of primary angioplasty only to culprit vessel versus complete revascularization guided by fractional flow reserve (FFR) in patients admitted pursuing an acute myocardial infarction with ST-segment elevation and have multiple injuries vessels. After a successful primary angioplasty to culprit artery, patients were randomized 1:1 to<a href="https://solaci.org/en/2015/06/24/danami3-primary-angioplasty-to-culprit-vessel-versus-multivessel-guided-by-ffr/" title="Read more" >...</a>

This double-blind study included 21162 patients with a history of acute myocardial infarction randomized to ticagrelor 90 mg e/12 h, ticagrelor 60 mg e/12 h or placebo. All patients received aspirin and had additional risk factors such as age or diabetes. The history of infarction should be between one and three years before being included<a href="https://solaci.org/en/2015/06/24/pegasus-timi-54-ticagrelor-plus-asa-in-stable-patients/" title="Read more" >...</a>

Current guidelines suggest treating only the culprit artery of myocardial infarction with ST-segment elevation. This prospective and randomized work included 296 patients in 7 centers suffering ST-segment elevation acute myocardial infarction referred for primary angioplasty randomized to treat only the culprit artery (n = 146) versus complete revascularization (n = 150).&nbsp; In the culprit artery<a href="https://solaci.org/en/2015/06/24/culprit-complete-revascularization-versus-culprit-artery-of-infarct-only/" title="Read more" >...</a>

The platelet P2Y12 receptor antagonist ticagrelor is shown to reduce the incidence of cardiovascular events when administered in hospital admission to patients suffering an ST-segment elevation acute myocardial infarction. Pre-hospital management that could improve coronary reperfusion and events like death or stent thrombosis was not studied. 1862 patients were included suffering ST-segment elevation acute myocardial<a href="https://solaci.org/en/2015/06/24/atlantic-administration-of-ticagrelor-in-the-ambulance-versus-in-the-cath-lab/" title="Read more" >...</a>

The HORIZONS-AMI and EUROMAX studies, had already shown that bivalirudin is superior to heparin plus inhibitors IIB / IIIA glycoprotein in reducing adverse clinical events in patients suffering an ST-segment elevation myocardial infarction undergoing primary angioplasty, at the expense of increase in the rate of acute stent thrombosis. This study included 2194 patients undergoing an<a href="https://solaci.org/en/2015/06/24/bright-bivalirudin-versus-heparin-versus-heparin-plus-tirofiban-in-primary-angioplasty/" title="Read more" >...</a>

There are experimental studies suggesting that metformin admin before and during ischemia and reperfusion could help to preserve left ventricular function regardless of glycometabolic state.In observational studies, the concomitant use of metformin is associated with a lower peak CK MB and troponin.380 nondiabetic patients undergoing primary angioplasty for acute coronary syndrome study with ST segment<a href="https://solaci.org/en/2015/06/24/gips-iii-metformin-does-not-improve-ejection-fraction-in-non-diabetic-patients-undergoing-primary-angioplasty/" title="Read more" >...</a>

&nbsp;IABP-SHOCK II: Intra-aortic balloon use impact on 30-day mortality in patients with cardiogenic shock.&nbsp; Holger Thiele2012-08-26 Original title:&nbsp;IABP-SHOCK II: Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock

Presentation Summary: The French National Registry included patients admitted with acute myocardial infarction between 1995 and 2010 (n = 6707). Over time, authors noted a reduction in the age of presentation, especially in women under 60 years with increased incidence of smoking and obesity. Pain-center time was significantly reduced, while increasing the number of patients<a href="https://solaci.org/en/2015/06/24/fast-mi-ami-improved-the-survival-associated-with-the-clinical-characteristics-changes-of-patients-in-the-french-national-registry/" title="Read more" >...</a>

The trial enrolled 200 patients post AMI treated with successful PCI, with LVEF &le;45% randomized to placebo, to receive early (before 7 days) or late (after 7 days) stem cells infusion. Primary end point was LVEF at 4 months. At follow up, stem cells infusion, both early and late, did not improve LVEF, compared to<a href="https://solaci.org/en/2015/06/24/swiss-ami-stem-cells-infusion-after-primary-angioplasty/" title="Read more" >...</a>

It is not clear so far whether pre-hospital fibrinolysis with early angiography could provide a clinical outcome similar to primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). This study included 1,892 patients who presented within three hours of symptom onset and who could not undergo primary angioplasty within the first hour. Patients were<a href="https://solaci.org/en/2015/06/24/stream-trial-it-is-time-to-check-out-facilitated-angioplasty/" title="Read more" >...</a>